The American Journal of Managed Care5 天
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Medscape6 天
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...
oncnursingnews11 天
FDA Approves Subcutaneous Use of Atezolizumab and Hyaluronidase-tqjs
The agency approved the subcutaneous injection of atezolizumab and hyaluronidase-tqjs for all of the adult indications as the intravenous formulation of atezolizumab. The FDA has approved the ...
GlobalData on MSN6 天
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
Multiple Sclerosis News Today7 天
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Cure Today10 天
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...